213 related articles for article (PubMed ID: 29870645)
21. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
[TBL] [Abstract][Full Text] [Related]
22. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.
Wray S; Havrdova E; Snydman DR; Arnold DL; Cohen JA; Coles AJ; Hartung HP; Selmaj KW; Weiner HL; Daizadeh N; Margolin DH; Chirieac MC; Compston DAS
Mult Scler; 2019 Oct; 25(12):1605-1617. PubMed ID: 30289355
[TBL] [Abstract][Full Text] [Related]
23. Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
Kocsik AS; Klein DE; Liedke M; Kaunzner UW; Nealon NM; Gauthier SA; Vartanian T; Perumal JS
J Neurol; 2018 May; 265(5):1226-1229. PubMed ID: 29666985
[TBL] [Abstract][Full Text] [Related]
24. Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis.
Akgün K; Blankenburg J; Marggraf M; Haase R; Ziemssen T
Front Immunol; 2020; 11():56. PubMed ID: 32082320
[No Abstract] [Full Text] [Related]
25. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
[TBL] [Abstract][Full Text] [Related]
26. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
27. A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis.
Herman JA; Khalighinejad F; York K; Radu I; Berrios Morales I; Ionete C; Hemond CC
Mult Scler Relat Disord; 2021 Jan; 47():102619. PubMed ID: 33189019
[TBL] [Abstract][Full Text] [Related]
28. Alemtuzumab treatment of multiple sclerosis.
Coles AJ
Semin Neurol; 2013 Feb; 33(1):66-73. PubMed ID: 23709214
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
30. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
31. Alemtuzumab therapy for multiple sclerosis.
Coles AJ
Neurotherapeutics; 2013 Jan; 10(1):29-33. PubMed ID: 23184314
[TBL] [Abstract][Full Text] [Related]
32. Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
Mult Scler; 2019 Dec; 25(14):1942-1945. PubMed ID: 30403365
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients.
Kim H; Lee EJ; Kim SK; Kim KK; Lim YM
Mult Scler Relat Disord; 2019 May; 30():247-251. PubMed ID: 30849681
[TBL] [Abstract][Full Text] [Related]
34. Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center.
di Ioia M; Di Stefano V; Farina D; Di Tommaso V; Travaglini D; Pietrolongo E; Sensi SL; Onofrj M; De Luca G
Mult Scler Relat Disord; 2020 Feb; 38():101504. PubMed ID: 31733426
[TBL] [Abstract][Full Text] [Related]
35. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
36. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
McCormack PL; Scott LJ
CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis.
Zmira O; Halpern AI; Abraham L; Achiron A
Acta Neurol Belg; 2021 Dec; 121(6):1513-1518. PubMed ID: 32447722
[TBL] [Abstract][Full Text] [Related]
38. The evolution of "No Evidence of Disease Activity" in multiple sclerosis.
Lu G; Beadnall HN; Barton J; Hardy TA; Wang C; Barnett MH
Mult Scler Relat Disord; 2018 Feb; 20():231-238. PubMed ID: 29579629
[TBL] [Abstract][Full Text] [Related]
39. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
[TBL] [Abstract][Full Text] [Related]
40. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
Fox EJ; Wynn D; Coles AJ; Palmer J; Margolin DH;
J Neurol Sci; 2016 Apr; 363():188-94. PubMed ID: 27000249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]